Galen
Article Abstract:
Galen plans to acquire Warner Chilcott, which would give the company a strong position in the US women's healthcare market, but also involves debt. Galen has developed an intravaginal drug delivery system which has yet to be tested commercially.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Galen
Article Abstract:
Galen's revenues have been boosted by acquiring Warner Chilcott, and the company has access to the US market, where sales may be easier than in Europe.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Schering
Article Abstract:
Schering has seen a drop in earnings of 13% for 1995, less than had been predicted by Guiseppe Vita, the company's chairman. Earnings and sales have been affected by currency fluctuations. Betaseron annual sales forecasts have been revised downwards and there are rival treatments for multiple sclerosis on offer. The drug is likely to be launched in Europe and elsewhere in 1996 and it is unclear whether it will perform as well as first expected.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic: